abstract |
The present disclosure relates to methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosus using fenebrutinib, an inhibitor of Bruton's tyrosine kinase, or a pharmaceutically acceptable salt thereof. |